Sara M Tolaney

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Follow-up care of patients with breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, 44 Binney Street, Mayer 2, Boston, MA 02115, USA
    Breast 16:S45-50. 2007
  2. ncbi Sarcoidosis mimicking metastatic breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Breast Cancer 7:804-10. 2007
  3. ncbi Lymphopenia associated with adjuvant anthracycline/ taxane regimens
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 8:352-6. 2008
  4. ncbi Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:5330-1. 2006
  5. ncbi Mechanisms of trastuzumab resistance in breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Agents Med Chem 9:348-55. 2009
  6. ncbi Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer
    Judy E Garber
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Cancer Inst 102:942-9. 2010

Detail Information

Publications6

  1. ncbi Follow-up care of patients with breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, 44 Binney Street, Mayer 2, Boston, MA 02115, USA
    Breast 16:S45-50. 2007
    ..With the growing number of breast cancer survivors, further studies should be undertaken to study the cost-effectiveness of surveillance strategies...
  2. ncbi Sarcoidosis mimicking metastatic breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Breast Cancer 7:804-10. 2007
    ..We describe 3 patients who presented with locally advanced breast cancer and who were found to have pulmonary findings for metastatic disease that were proven upon biopsy to be consistent with sarcoidosis...
  3. ncbi Lymphopenia associated with adjuvant anthracycline/ taxane regimens
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 8:352-6. 2008
    ....
  4. ncbi Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:5330-1. 2006
  5. ncbi Mechanisms of trastuzumab resistance in breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Agents Med Chem 9:348-55. 2009
    ..In this review, we discuss the mechanisms of antitumor activity of trastuzumab, potential mechanisms contributing to its resistance, and novel therapeutic agents that may provide a means to overcome trastuzumab resistance...
  6. ncbi Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer
    Judy E Garber
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Cancer Inst 102:942-9. 2010
    ..We investigated whether FVL was associated with TE risk in women with early-stage breast cancer who took adjuvant tamoxifen...